Iron Triangle Partners LP Has $22.49 Million Position in Glaukos Co. (NYSE:GKOS)

Iron Triangle Partners LP trimmed its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 31.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 150,000 shares of the medical instruments supplier's stock after selling 67,674 shares during the quarter. Glaukos accounts for about 2.5% of Iron Triangle Partners LP's portfolio, making the stock its 18th biggest holding. Iron Triangle Partners LP owned 0.27% of Glaukos worth $22,491,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of GKOS. IFP Advisors Inc acquired a new position in shares of Glaukos in the 4th quarter worth $43,000. Asset Planning Inc acquired a new position in shares of Glaukos in the 4th quarter valued at $90,000. CoreCap Advisors LLC increased its stake in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares in the last quarter. Picton Mahoney Asset Management acquired a new stake in Glaukos during the 4th quarter worth about $125,000. Finally, SBI Securities Co. Ltd. purchased a new stake in Glaukos during the fourth quarter valued at about $153,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.80% of the company's stock.

Glaukos Stock Up 4.2%

Shares of GKOS traded up $3.83 during midday trading on Friday, reaching $95.45. 773,079 shares of the stock were exchanged, compared to its average volume of 685,745. The company has a market cap of $5.45 billion, a price-to-earnings ratio of -33.26 and a beta of 0.83. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $77.10 and a 12-month high of $163.71. The firm has a 50 day simple moving average of $93.95 and a 200-day simple moving average of $126.28.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. During the same quarter last year, the firm earned ($0.70) earnings per share. The company's revenue for the quarter was up 24.6% on a year-over-year basis. Research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the topic of several analyst reports. Truist Financial reissued a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Needham & Company LLC decreased their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 16th. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $160.00 to $86.00 in a report on Thursday, May 1st. Finally, Morgan Stanley lowered their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.